August 07, 2014 8:30am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK )
will announce top line data from the first of two identical pivotal
Phase 3 clinical trials for RAYALDEE™ and its second-quarter 2014
financial results on Monday, August 11, 2014, after the market closes.
OPKO's senior management team will host a conference call and live audio
webcast at 8:30 a.m. ET on Tuesday, August 12, 2014 to discuss the Phase
3 data and the Company's results in greater detail.
The conference call will be available via phone and webcast. The
conference call dial-in information is listed below. To access the
webcast, please log on to the OPKO website at www.opko.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required. A link to the live
webcast is also included below.
WHEN: Tuesday, August 12, 2014, 8:30 a.m. ET
DOMESTIC & CANADA DIAL-IN: 1-201-689-8562
INTERNATIONAL DIAL-IN: 1-877-407-0789
LIVE WEBCAST LINK: http://public.viavid.com/index.php?id=110543
For those unable to participate in the conference call or webcast, a
replay will be available beginning August 12, 2014 at 11:30 a.m. ET
until September 12, 2014 at 11:59 p.m. ET. To access the replay, dial
1-877-870-5176 or 1-858-384-5517. The replay passcode is 13588800.
The replay can also be accessed for 30 days on OPKO’s website at www.opko.com .
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies.
FTI Consulting
Barbara Ryan,
Managing Director
or
Media
Kimberly Ha, 212-850-5612
Senior Director
Source: OPKO Health, Inc.
Released August 7, 2014
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page